Skip to content Skip to footer
Subscribe Now
INSIGHTS+

Know Your Investor: Cormorant Asset Management (September’25 Edition) 

Shots:  Welcome to the September edition of Know Your Investor, featuring leading investors fuelling healthcare & life sciences  This edition spotlights Cormorant Asset Management, an investment firm focused on biotechnology and healthcare companies  In 2024, Cormorant completed 31 investments ~$3.88B, spanning PIPEs, private financings, IPO, and venture rounds. For the full report, contact us at…
September 4, 2025

Read more

Biopharm Top 20 2023
TOP 20

Top 20 Biopharma Companies of 2024

Shots: Driven by innovations and propelled by the pursuit of delivering the best-in-class therapies, 2023 remained a good year for the Biopharma Industry, despite a slight revenue decline, partly due to the conclusion of the COVID-19 pandemic With a CAGR of 7.8 %, the global biopharma industry is anticipated to register a market size of…
April 11, 2024

Read more

A Complete Account of EMA Approvals in 2023
INSIGHTS+

A Complete Account of EMA Approvals in 2023

Shots:  In 2023, EMA approved around 45 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, genetics, pulmonary, otolaryngology, gastroenterology, ophthalmology, and endocrinology  PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, & Dermatology  For…
March 5, 2024

Read more